Success Metrics

Clinical Success Rate
77.8%

Based on 7 completed trials

Completion Rate
78%(7/9)
Active Trials
3(21%)
Results Posted
71%(5 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_2
3
21%
Ph early_phase_1
1
7%
Ph not_applicable
4
29%
Ph phase_1
2
14%
Ph phase_3
1
7%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Early Phase 1First-in-human
1(9.1%)
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
1(9.1%)
N/ANon-phased studies
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.0%

7 of 10 finished

Non-Completion Rate

30.0%

3 ended early

Currently Active

3

trials recruiting

Total Trials

14

all time

Status Distribution
Active(4)
Completed(7)
Terminated(3)

Detailed Status

Completed7
Active, not recruiting2
Terminated2
Recruiting1
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
3
Success Rate
77.8%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (9.1%)
Phase 12 (18.2%)
Phase 23 (27.3%)
Phase 31 (9.1%)
N/A4 (36.4%)

Trials by Status

active_not_recruiting214%
recruiting17%
completed750%
terminated214%
withdrawn17%
not_yet_recruiting17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT04396860Phase 2

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Completed
NCT02933489Not Applicable

Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts

Active Not Recruiting
NCT06448286Phase 3

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

Not Yet Recruiting
NCT02156739Not Applicable

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

Active Not Recruiting
NCT05937776

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

Recruiting
NCT03045497Phase 1

Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads

Completed
NCT00577798

Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

Completed
NCT01869725Phase 2

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Completed
NCT03280277Early Phase 1

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

Terminated
NCT02277561Not Applicable

Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery

Withdrawn
NCT01940081

The Leiden Nonischemic Cardiomyopathy Study

Completed
NCT02587663Not Applicable

Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI

Completed
NCT02429804Phase 1

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Terminated
NCT00639509Phase 2

IMC-A12 in Treating Patients With Advanced Liver Cancer

Completed

All 14 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
14